Thursday, 31 August 2017

German city of Aachen offers iodine tablets amid nuclear fears

Only 70 kilometers separate Aachen from the Tihange nuclear plant in Belgium. Many residents have long had concerns about the safety of the facility. Now, the city is offering iodine tablets in case of an accident.

People in Aachen often feel uneasy about their proximity to the Belgian border, and the controversial Tihange nuclear power plant located some 70 kilometers (43 miles) away. Parts of the plant are more than 40 years old. The oldest block was meant to be taken offline two years ago. Repeated reports about newly discovered cracks in the reactors send collective shivers through Aachen's population. Now, local authorities are taking a preventative measure. Starting on Friday, residents can order free iodine tablets online, in the event of a major accident in Tihange.

Usually, iodine tablets are stored in a central location, and only distributed in an emergency. But Markus Kremer, the Aachen city official in charge of environmental issues, said the city came to the conclusion that the tablets couldn't be distributed quickly enough in the case of an accident at Tihange. "That's how we had the idea of supplying a large part of the population with iodine tablets in advance," he said.

The tablets could help prevent thyroid cancer in case of radioactive contamination, and are aimed primarily at children, breastfeeding mothers and people under the age of 45. For all other people, the risk of side effects outweighs the likelihood of one day contracting thyroid cancer.

In Aachen, Markus Kremer (DW/S. Schröder)

Aachen city official Kremer believes it's important to supply residents iodine tabets in advance of a disaster

'Don't want to downplay the risks'

Kremer says the city is aware that such a preventative measure could have the unwanted effect of further unsettling Aachen residents. "In everything we've done so far, we've tried to find a sensible way of communicating the necessary information. On the one hand, there is absolutely no point in people panicking, but we also don't want to downplay the risks." Authorities estimate that more than a third of residents will take advantage of the free tablets.

Belgium's nuclear plants have also mobilized Aachen residents in other ways. Many windows and car bumpers sport stickers and flyers calling for Tihange to be closed down. This summer, activists formed a human chain stretching 90 kilometers along the road from Tihange to Aachen in protest of the power plant.

Local pharmacist Gabriele Neumann said there was already demand for iodine tablets before the city launched its distribution program. "There was particularly large demand around 18 months ago when Tihange was shut down and then restarted a few times," she said, adding her pharmacy alone sold more than 300 packages of iodine tablets at the time.

Aachen Flyer calling to close Tihange (DW/S. Schröder)

Many Aachen residents have displayed signs calling for the Tihange plant's closure

Tablets 'only a first step'

But iodine tablets alone are not nearly enough if citizens seriously want to prepare themselves for a large-scale nuclear accident, said Hans-Josef Allelein, an expert on reactor safety and reactor technology at Aachen's technical university. "We need to be clear: that's just a first step. I personally don't think this fear is founded, but if you have this fear, you should also stockpile two liters of water per person, basic food supplies, vitamin tablets, rubber boots and materials you can use to seal your doors and windows," said Allelein. But he's critical of the debate about iodine tablets specifically, and Tihange in general, saying the tone has been too hysterical. And he takes particular issue with a study commissioned on the Aachen region, outlining possible scenarios in the event of a major accident at the plant.

The study, conducted by the Institute for Security and Risk Assessment at the University of Vienna, concluded that in the event of an accident at Tihange, the Aachen region would very likely be affected by radioactive radiation. Furthermore, the study said that, depending on weather patterns, the levels of radioactivity could reach those seen during the 1986 Chernobyl disaster, leading to widespread evacuations.

Hans-Josef Allelein Professor at the University of Aachen (picture-alliance/dpa/A. Levay)

Allelein says iodine tablets are 'just a first step' when preparing for a nuclear disaster

Government: No basis for conclusions

At the end of last year, Green party lawmaker Sylvia Kotting-Uhl submitted a parliamentary question to the federal government in which she referred to the results of the study from Vienna. The government responded at the start of this year, saying that the study did not adequately describe the disaster and emergency measures, and that it could therefore not be used as the basis for any firm conclusions.

Even though physicist Allelein personally feels that fears about a nuclear disaster at Tihange are unfounded, he does agree with one aspect of the criticism directed at the Belgian operators of the power plant: "I have the feeling that the Belgian operators and also Belgium's Federal Agency for Nuclear Control only ever release information once it's somehow been released elsewhere."

  • Does nuclear power have a future? Deadly disaster

    The worst nuclear disaster of all time, the explosion at Chernobyl nuclear plant in Ukraine released massive amounts of radiation into the atmosphere. Areas close to the plant - in Ukraine, Belarus and Russia - were heavily contaminated. Heightened levels of radiation were also measured across most of Europe. The "exclusion zone" around Chernobyl remains off-limits to human habitation today.

  • Does nuclear power have a future? It happens again

    After a magnitude-9 earthquake and consequent tsunami, three nuclear reactors at Fukushima power plant in Japan went into meltdown in March 2011. There were also four hydrogen explosions. The accident released 500 times as much radioactive cesium-137 as the nuclear bomb dropped on Hiroshima in 1945. The clean-up is expected to take decades.

  • Does nuclear power have a future? Sickening impact

    After Chernobyl, thousands of people developed cancer. In Japan too, the heavily contaminated region of Fukushima, where 200,000 people lost their homes, saw cases of the disease escalate. The number of children with thyroid cancer there is 20 times higher than other regions.

  • Does nuclear power have a future? Rallying against nuclear power

    Chernobyl fueled public opposition to nuclear power, particularly in Europe. The same happened after Fukushima. Before the Japanese disaster, the country relied on nuclear for 30 percent of its power. That has fallen to 1 percent. The government wants to continue producing nuclear power and plans to reinstall some reactors. But affected regions have successfully pushed back those plans.

  • Does nuclear power have a future? Nuclear industry in crisis

    Today, the nuclear power sector is deep in economic crisis. In Japan, the United States and France, nuclear power plants run at a loss, and construction projects for new reactors have been postponed.

  • Does nuclear power have a future? New-build set-backs

    France had high hopes for its newest nuclear reactors - called pressurized water reactors (PWRs). This technology was supposed to be safe, and the Flamanville power plant was due to be switched on in 2012. Due to security issues, that's been pushed back to 2018 at the earliest. The project will cost more than 10 billion euros - three times the original budget.

  • Does nuclear power have a future? Great Britain plans new reactors

    For years, the UK has been planning to build two new PWR reactors at Hinkley Point. Costs are estimated at 33 billion euros and groundbreaking is slated for 2019. But doubts are growing over its economic viability. The electricity it produces will be much pricier than solar or wind power, and will need subsidies to compete in the market.

  • Does nuclear power have a future? Aging reactors up for grabs

    Nuclear power plants used to be lucrative. But now, many are old and frail. Repair costs often mean they cannot turn a profit. Swiss energy corporation Alpiq recently tried to give away two of its old plants, 33 and 38 years old, to French energy company EDF - which declined the offer.

  • Does nuclear power have a future? Disasters abroad prompt German phase-out

    Three decades ago, the Chernobyl disaster galvanized Germany's anti-nuclear movement, which is often cited as the roots of the country's energy transition. In 2002, Germany passed a law that would have seen the last reactor shut down in 2022. The plan was later scrapped by Angela Merkel's government. But after Fukushima, Merkel quickly reversed her decision and the phase-out was back on track.

  • Does nuclear power have a future? Switching them off

    So far, nine of Germany's reactors have gone offline, with eight more to follow by 2022. To finance the costs of nuclear waste disposal, plant operators must pay 23.6 billion euros into a federal fund. The operators themselves are responsible for the similarly costly process of dismantling the plants, which will take decades to complete.

  • Does nuclear power have a future? Growing fear of accidents

    Across the EU and Switzerland 132 nuclear reactors are still online. They were designed to operate for 30 to 35 years - their average age is now 32 years. Malfunctions and security issues are frequently detected and protestors are increasingly calling for plants to be shut down.

  • Does nuclear power have a future? China pushes on with nuclear

    No new nuclear power plants have been built in the EU, Japan or Russia since the Fukushima disaster in 2011. China remains committed to nuclear, partly to replace coal-based power. But the country is also upping investment in wind and solar.

    Author: Gero Rueter (sst,jf)


  • Source: German city of Aachen offers iodine tablets amid nuclear fears

    Wednesday, 30 August 2017

    Toro Releases AquaFlow Tablet App for On-The-Go Field Designs

    Printer-friendly versionPrinter-friendly version

    August 30, 2017

    Toro is pleased to announce the release of a tablet app for its popular drip irrigation design software, AquaFlow™, available for both Apple and Android tablet devices, simplifying the drip irrigation design process and accessibility to drip irrigation design information.

    Read More

    New MyToro App Puts Toro Equipment Owners in Control

    August 23, 2017

    Homeowners with a Toro® mower or snowblower now can access essential product information on their smartphone, thanks to the all-new MyToro mobile app (www.toro.com/mytoro). It's the latest way Toro is helping customers take charge of their yard, by delivering the resources they need, when they need them, to get the best possible performance out of their Toro equipment.

    Read More

    Proven Wireless Sensor Technology That Takes Watering Smart to the Next Level

    August 14, 2017

    We rely on technology every day in our cars, homes and offices. Putting technology to work in the landscape can take the guess work out of watering. Combining your expertise with Toro's technology means your customers can create and maintain a sustainable, WaterSmart® lawn with less hassle.

    Read More

    Investment Brings Dividends to 'Loveliest Castle in the World'

    August 8, 2017

    Leeds Castle in Kent is at the conclusion of a two-year project to revitalize the golf course and clubhouse. The extensive project ends with the installation of Toro irrigation on all the greens, approaches and fairways of the nine-hole golf course, and around the lawns of the Castle island. 

    Read More

    Toro Launches GrandStand® MULTI FORCE® Power Broom Attachment

    July 31, 2017

    Adding to the versatility of the Toro® GrandStand® MULTI FORCE® stand-on mower, Toro is introducing a power broom attachment for multi-season use. The power broom is designed for clearing snow off sidewalks and driveways, as well as clearing debris or dethatching grass.

    Read More

    Copy this html code to your website/blog to embed this press release. <a href="http://www.pressreleasepoint.com/toro-releases-aquaflow-tablet-app-go-field-designs" class="active">Toro Releases AquaFlow Tablet App for On-The-Go Field Designs</a>


    Source: Toro Releases AquaFlow Tablet App for On-The-Go Field Designs

    Monday, 28 August 2017

    Xplore Secures Additional Rugged Tablet Order from Main Roads WA in Western Australia

    Government-affiliated organisation using F5m tablets for large-scale road inspection, maintenance

    SYDNEY, Australia—August 29, 2017— Xplore Technologies Corp. (NASDAQ: XPLR) today announced that Main Roads WA, the State road authority for Western Australia, has ordered additional Xplore F5m rugged tablet PCs to simplify the oversight of the region's roads and enforce its high-quality transportation standards. The organisation uses the tablets in the planning, construction and maintenance of an integrated and efficient world-class road network that spans more than 2.5 million square kilometres. Specifically, road inspectors use the vehicle-mounted Xplore F5m tablet to retrieve asset information and access GIS systems for the real-time recording and tracking of maintenance issues and new project requirements.

    "Main Roads WA is not just responsible for managing more than $41 billion road assets in Western Australia, they are required to maintain one of the most widely geographically distributed highway and main road networks in the world," explained Brett Gross, ANZ Director of Xplore. "The Xplore F5m rugged tablet enables their field teams stay completely connected to their network, and each other, at all times despite the physical disparity of their job sites. This has led to significant productivity gains and cost savings over the last five years. Road inspectors now have the tools to more efficiently plan their routes and execute maintenance actions on site in real time, which minimises undue truck rolls and, subsequently, reduces wasteful operational expenditures."  

    Main Roads WA first deployed F5m tablets in 2012 as part of a custom-tailored, in-vehicle mounted solution that was designed in collaboration with Xplore's Solution Architects and Datanet, the Xplore partner also fulfilling this current order. The State road authority ultimately chose to standardise on the Xplore rugged tablet solution that same year because it was the only mobile computing platform that met the stringent security, safety and connectivity requirements of their government partners. 

    "From the start, the customer made it clear that they required a non-invasive mobility solution for their entire fleet," added Jerry Clarke, Business Development Manager, Datanet. "One of the biggest advantages of the Xplore F5m rugged tablet has been its flexibility in that manner. The installation of the F5m has been very simple and straightforward despite the unique ergonomic considerations of the 37 different vehicle makes and models we have equipped in Main Roads' fleet. Plus, Xplore's mounted mobility solution was also the only one to easily pass the Department of Transport's Vehicle and Safety Standards inspection and Australian Design Rules certification. Main Roads had long struggled to meet safety regulations with their previous Toughbook system."

    The lightweight, 10.4" Xplore F5m tablet has also empowered Main Roads WA to go completely paperless and streamline their broader IT requirements by providing a single and complete "mobile office" solution. Road inspectors often take the "grab and go" Windows® and Intel®-powered mobile computers out of the vehicle and into the field and office for continuity in workflows. 

    "The F5m's bright sunlight-readable display, embedded 4G XLTE mobile broadband, integrated barcode scanners and annotated image capture make data-intense tasks easy to complete anywhere," Clarke continued. "The tablet is also tolerant of road vibration and shocks, as well as the extreme temperatures that can be experienced in Western Australia. Plus, it is C1D2/C1Z2 compliant for safe use in explosive environments, which is critical during road construction projects."

    For more information on Xplore and its complete lineup of rugged tablet solutions for government organisations, please visit www.xploretech.com/[SZ1]government. Information about the Xplore F5m rugged tablet platform can be found at www.xploretech.com/F5m. 

    For all further media enquiries or to read a detailed case study about the business process improvements and cost savings that Main Roads WA has achieved since deploying the Xplore "work-anywhere" mobility solution, please contact Monique on mscerreto@gmail.com or 0416 282 464.

    About Xplore Technologies

    Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors.   The company's award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail.  Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialised workflow demands. Follow us on Twitter, Facebook, LinkedIn, and YouTube. Forward Looking Statements

    This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.  


    Source: Xplore Secures Additional Rugged Tablet Order from Main Roads WA in Western Australia

    Sunday, 27 August 2017

    Suprema SFU-S20 fingerprint module integrated in BioRugged's BioWolf LCC tablet PC

    SEOUL, KOREA, Aug 24, 2017 - (ACN Newswire) - Suprema, a global leader in biometrics and ID solutions, announced that the company's SFU-S20 fingerprint modules are integrated into the new BioRugged LCC, an affordable 5" Mobile Android terminal from BioRugged. SFU-S20 is an FBI PIV and FAP20 certified USB fingerprint scanner designed to provide a high-level biometric security solution for identity management applications. The SFU-S20 features a slim optical sensor with a larger platen and the latest anti-spoofing (live fingerprint detection) technology.

    BioRugged LCC follows the release of the BioWolf LE rugged tablet earlier this year and addresses more price sensitive markets, while also offering a ruggedized option with the same state of the art biometrics for highly mobile environments. The BioRugged LCC mobile Android platform is suitable for various application including census, voter registration, workforce management, logistics, health care, industrial protection and ban king.

    An ideal fit for the LCC are projects that focus on biometric enrolment and verification, linked to location based statistics and security. The BioRugged LCC features GPS, WIFI, Bluetooth and a 2MP/8MP auto focus front-back camera. A large capacity battery ensures maximum uptime with up to 150 enrolments per charge over 3/4G (LTE) or WIFI connections. The IP67 Rugged PDA is equipped with Gorilla Glass and NFC capability.

    Although suitable for any biometric identity solution, the BioRugged LCC has attracted huge attention in the mobile T&A and workforce management markets. Its affordability and portability now allows for effective time management in the field where static biometric readers will not fulfill the requirements. Integrated into Suprema's BioStar 2 time management platform it enables the integration of mobile and static biometric terminals under one platform. BioRugged LCC can now conveniently perform biometric authentication and time management and h ave great potential for construction sites, agricultural operations, outsourced security and cleaning services or any environment where the workforce does not report at an office. Incorporation of GPS unitization locations also adds another dimension to T&A and workforce management which identifies fraud attempts and offers ideal GIS data for real-time workforce optimization.

    Upon launching in January 2017, BioRugged LCC has already shipped over 9000 units, to be used in public and commercial projects including SIM card registration (telco-KYC) in the African market. "We are very excited about the BioRugged LCC, a truly versatile mobile platform secured by best fingerprint technology available today. The BioRugged LCC was engineered to be compatible in various scenarios in the Biometric mobile environment," said Hof Retief, CEO at BioRugged.

    "BioRugged is our strategic partner, and at Suprema, we are proud of SFU-S20/S21 USB fingerprint module being featured on this new LCC. We look forward to working together on future innovations and will strive to deliver highest-standard biometrics for BioRugged's customers," said Bogun Park, CEO at Suprema.

    For more information, please visit www.supremainc.com or contact us at [email protected].

    About Suprema Inc.

    Suprema is a leading global provider of biometrics and ID solutions. By combining world renowned biometric algorithms with superior engineering, Suprema continually designs and develops industry-leading products and solutions. Suprema's extensive range of portfolio includes fingerprint authentication/enrollment scanners and e-Passport readers. Suprema has worldwide sales network in over 130 countries and is one of the world's Top 50 security company in its turnover (ranked in A&S's Security 50, 2010-2015). For more information, please visit www.suprema-id.com.

    Contact:

    Andy Ahn Head of Marketing, Suprema Inc. Email: [email protected] Source: Suprema Inc.Topic: Press release summarySectors: Security/Biometricshttp://www.acnnewswire.comFrom the Asia Corporate News Network

    Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


    Source: Suprema SFU-S20 fingerprint module integrated in BioRugged's BioWolf LCC tablet PC

    Friday, 25 August 2017

    Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients

    Printer-friendly versionPrinter-friendly version

    Daiichi Sankyo Company, Limited (headquarters: Chuo-ku, Tokyo; hereafter referred to as "Daiichi Sankyo") and UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo; hereafter referred to as "UCB Japan"; when referring to the global UCB group, "UCB") are pleased to announce today that VIMPATÒ Tablets 50 mg and 100 mg (generic name: lacosamide) has been approved for monotherapy for partial-onset seizure (including secondary generalized seizures) in adult patients with epilepsy.

     

    VIMPAT® is a novel antiepileptic drug with a new mechanism of action which differs from that of existing antiepileptic drugs*1,2,3. Specifically, VIMPAT® suppresses excessive excitation of neurons by selectively promoting gradual inactivation of potential-dependent Na channels*4. It had already been approved for partial-onset seizure (including secondary generalized seizures) in adult patients with epilepsy in combination with other agents, as a result of partial amendment of approval, today VIMPAT® was approved for monotherapy.

     

    The number of patients in Japan with epilepsy is estimated to total about one million with approximately 57.000 new patients every year*5. Even today epilepsy remains a disease with unmet medical needs for which a great majority of patients require long-term pharmacotherapy*6 and for which over 30% of patients reportedly are unable to adequately control seizures despite treatment with existing antiepileptic drugs*7.

     

    Daiichi Sankyo and UCB expect VIMPAT® to be able to further contribute to patients and healthcare providers by making it possible to use it as a monotherapy.

     

     

    Product Profile

    Brand name

    VIMPAT® Tablets 50 mg and 100 mg

    Generic name (JAN)

    Lacosamide

    Indication

    Partial-onset seizure (including secondary generalized seizures) in patients with epilepsy

    Dosage and administration

    For adults, the recommended starting dose of lacosamide is 100 mg/day, which should be increased to an initial therapeutic dose of 200 mg/day at intervals of at least 1 week, each given orally in two divided doses. However, depending on response and tolerability, the maintenance dose can be further increased to a maximum recommended daily dose of 400 mg, and dose increments should be made within doses of 100 mg/day at an interval of at least 1 week.

    Date of approval

    July 4, 2016

    Date of listing in the NHI reimbursement price list

    August 31, 2016

    Date of launch

    August 31, 2016

    Date of partial amendment of approval

    Monotherapy indication: August 25, 2017

    Marketing authorization holder

    UCB Japan Co., Ltd.

    Marketed by

    Daiichi Sankyo Company, Limited

    About VIMPAT® (generic name: lacosamide)

    VIMPAT® is a novel antiepileptic drug with a new mechanism of action which differs from that of existing antiepileptic drugs*1,2,3. Specifically, it suppresses excessive excitation of neurons by selectively promoting gradual inactivation of potential-dependent Na channels*4. Its usefulness was demonstrated in a Japan-China collaborative Phase 3 clinical trial in adult patients (aged 16 and over) with partial-onset seizures including Japanese patients*8 and a long-term extended trial*9. Based on results of these clinical trials, VIMPAT® was approved in Japan for "adjunctive therapy for partial-onset seizures in patients with epilepsy" in July 2016. In Japan, Daiichi Sankyo and UCB concluded a licensing agreement in November 2014. Based on that agreement, UCB manufactures and supplies the product, while Daiichi Sankyo manages distribution and books sales. Promotion is carried out jointly by both companies. 

    VIMPAT® was approved for "monotherapy for partial-onset seizures in patients with epilepsy" in the USA in August 2014 and Europe in December 2016.

     

    About epilepsy

    Epilepsy affects approximately 65 million people around the world with a prevalence of about 1%. It may occur over a wide age range from infants to senior citizens and its incidence does not vary much across countries, geographies, genders or races. The number of patients with epilepsy is estimated to total about one million in Japan with approximately 57.000 new patients every year*5. Epilepsy is a disease with unmet medical needs even today with a great majority of patients needing long-term pharmacotherapy*6 and over 30% of patients reportedly being unable to adequately control seizures despite treatment with existing antiepileptic drugs*7.  

    Seizures associated with epilepsy are classified into three major groups based on their clinical symptoms: partial-onset seizures (which may sometimes progress to secondary generalized seizures), generalized seizures, and unclassified seizures. Partial-onset seizures show the highest incidence among these three types accounting for approximately 60% of the total. 

     

    About UCB in epilepsy

    UCB has a rich heritage in the field of epilepsy with more than 20 years of experience in research and development of anti-epileptic drugs. As a company with a long-term commitment to epilepsy research, our goal is to provide solutions that help patients improve their QDL with a focus on unmet medical needs. Our scientists are proud to contribute to advances in the understanding of epilepsy and its treatment. We share goals, cooperate, and create advanced networks with world-leading scientists and clinicians in academic institutions, pharmaceutical companies and other organizations. At UCB, we are inspired by patients and driven by science in our commitment to support patients with epilepsy.

     

    References

    *1: Vilin YY. et al: Cell Biochem Biophys. 35(2), 171-190, 2001

    *2: Beyreuther BK. et al: CNS Drug Rev. 13(1), 21-42, 2007

    *3: Rogawski MA. et al: Epilepsy Res. 110, 189-205, 2015

    *4: Errington AC. et al: Mol Pharmacol. 73(1), 157-169, 2008

    *5: The Japan Epilepsy Society: Guidebook for Epileptologists (in Japanese), Shindan to Chiryo Sha Inc., 2014

    *6: Perucca E. : Baillière's Clin Neurol. 5(4), 693-722, 1996

    *7: Kwan P. et al : N Engl J Med. 342(5), 314-319, 2000

    *8: Hong et al: Epilepsy Res 127, 267–275, 2016

    *9: Application dossier (long-term extended study on adjunctive therapy for partial-onset seizures in Japan and China) (in Japanese)

     

     

    About Daiichi Sankyo

    Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.

     

    About UCB

    UCB, based in Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases including those of the central nervous system or the immune system. With more than 7,500 people in approximately 40 countries, the company generated revenue of € 4.2 billion (about \500 billion) in 2016. UCB is listed on Euronext Brussels (symbol: UCB).

    Established in 1988, UCB Japan markets a number of products. The anti-epileptic drug E Keppra®, VIMPAT® and the TNF-α inhibitor CIMZIA® will be a platform for further growth. As a biopharma leader, UCB Japan is dedicated to making a continuing contribution to the treatment and health of patients with severe diseases such as neurology and immunology/inflammatory diseases.

    Copy this html code to your website/blog to embed this press release. <a href="http://www.pressreleasepoint.com/antiepileptic-vimpat-tablets-50-mg-and-100-mg-approved-monotherapy-partial-onset-seizures-epilepsy" class="active">Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients</a>


    Source: Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients

    Thursday, 24 August 2017

    Verizon says goodbye to original unlimited data plan, 1080p streaming and hello to throttling

    That didn't last long. 

    After Verizon made splashy news introducing an unlimited data plan with full 1080p video streaming six months ago -- touching off a price war with the other big carriers -- the company has replaced the popular option with four new plans starting Aug 23. 

    In February, the largest U.S. cellular carrier, long a holdout on unlimited plans, announced unlimited 4G data, talk and text (with AutoPay) for $80 per month. Family plans were $45 per line for four lines. 

    The other carriers followed Verizon's lead, which essentially ended overage chages for data and drove down the price for cellular service. 

    Now, Verizon has "evolved" its single plan, which was slowing network speed for all users, by splitting the original unlimited plan it into four new options that do away with unlimited video streaming in 1080p resolution unless customers are willing to pay more. Verizon also will begin slowing data speeds -- known as throttling --  at times of networ congestion. 

    Most dramatic, Verizon Unlimited "legacy" customers to signed up for unlimited service before Wednesday automatically will be downgraded to 720p video streaming (DVD quality), according to the release. To offset the change, the company added an additional 5 GB mobile hot spot data (now it's 10 GB total) at no additional charge. Tablets uses still get  1090p streaming.

    Here's a look at the new plans: 

    Go Unlimited: Unlimited talk and text, 4G LTE 480p ("DVD quality streaming) and mobile hot spot at 600 kbps. 1 line: $75 a month; 4 lines: $160 a month with AutoPay. Data will be throttled at times of congestion.  Taxes and fees are extra.

    Beyond Unlimited: Unlimited talk and text, unlimited 4GLTE 720p "HD quality streaming") and 15 GB mobile hot spot. 1 line: $85 a month; 4 lines: $200 a month with AutoPay. Data will be throttled at 22 GB in most instances. Taxes and fees are extra.

    Business Unlimited: Unlimited talk and text, premium unlimited 4G LTE 480p and unlimited mobile hot spot with first 10 GB LTE. 1 line: $85 a month; 4 lines: $200 a month. Data will be throttled at 22 GB in most instances. Taxes and fees are extra. 

    Prepaid Unlimited: Unlimited talk and text, Unlimited 4G LTE 480p and calling to Mexico and Canada. 1 line: $80 a month.

    After Verizon and AT&T began offering unlimited data plans for $180 a month for four lines, T-Mobile and Sprint also announced improvements to their unlimited plans. But the new unlimited plans are clogging networks and slowing data speeds, according to an August report by OpenSignal, which compares 3G and 4G performance of the four largest mobile operators.

    This prompted Verizon's changes. 

    "We're doing this to ensure all customers have a great experience on our network since there is no significant difference in quality on a smartphone or tablet when video is shown at higher resolutions (than 720p on phones and 1080p on tablets)," Verizon said in the release. 

    Click here to learn more about Verizon's new plans. 

    Connect with me: "Like" Doreen's Deals on Facebook; follow Doreen Christensen on Twitter, Facebook and GooglePlus; sign up for my Freebie Friday Newsletter.

    RELATED STORIES: 

    T-Mobile's new senior plan offers big savings

    Comparing new unlimited data plans from the Big Four carriers

    Verizon offering unlimited data plans


    Source: Verizon says goodbye to original unlimited data plan, 1080p streaming and hello to throttling

    Wednesday, 23 August 2017

    Free Bonus! Free Bonus! Worldwide fastest delivery for Topamax pills of best quality! Topiramate extended release tablet strengths!

    Topiramate is used to treat convulsions, epilepsy in children and adults, and also to prevent migraines and certain psychiatric conditions.

    Package

    Price

    Per Pills

    Savings

    Order

    25 mg x 30 pills

    $43.99

    $1.47

    $0.00

    25 mg x 60 pills

    $72.99

    $1.22

    $15.00

    25 mg x 90 pills

    $98.99

    $1.10

    $33.30

    25 mg x 120 pills

    $119.99

    $1.00

    $56.40

    25 mg x 180 pills

    $163.99

    $0.91

    $100.80

    25 mg x 360 pills

    $298.99

    $0.83

    $230.40

    Package

    Price

    Per Pills

    Savings

    Order

    50 mg x 30 pills

    $41.99

    $1.40

    $0.00

    50 mg x 60 pills

    $66.99

    $1.12

    $16.80

    50 mg x 90 pills

    $90.99

    $1.01

    $35.10

    50 mg x 120 pills

    $108.99

    $0.91

    $58.80

    50 mg x 180 pills

    $146.99

    $0.82

    $104.40

    50 mg x 240 pills

    $175.99

    $0.73

    $160.80

    50 mg x 360 pills

    $237.99

    $0.66

    $266.40

    Package

    Price

    Per Pills

    Savings

    Order

    100 mg x 30 pills

    $77.99

    $2.60

    $0.00

    100 mg x 60 pills

    $124.99

    $2.08

    $31.20

    100 mg x 90 pills

    $167.99

    $1.87

    $65.70

    100 mg x 120 pills

    $201.99

    $1.68

    $110.40

    100 mg x 180 pills

    $272.99

    $1.52

    $194.40

    100 mg x 240 pills

    $327.99

    $1.37

    $295.20

    Product Description

    Common useTopiramate belongs to a group of anticonvulsant drugs. It is applied in treatment of epilepsy in children and adults. It is also used to treat essential tremor, bulimia nervosa, obsessive-compulsive disorder, alcoholism, smoking cessation, neuropathic pain, etc.

    Dosage and directionTake Topamax by mouth with a glass of water, with or without food. Avoid cutting, crushing or chewing this medicine.Do not take the medicine more often than it is prescribed. Do not give up taking it except on the advice of your doctor.It may need time for the medicine to help.Consult your doctor concerning proper dose for you.

    PrecautionsInform your health care professional if you have any allergies or if you have glaucoma, heart or lung disease, kidney or liver problems.Avoid drinking alcohol and smoking while being treated with this medication.Aged people can be more sensitive to side effects of the medicine.Inform your doctor if you are pregnant or breast-feed.

    Contraindications Topamax should not be used by patients having demonstrated a reaction of hypersensitivity to it.

    Possible side effectsThe most common side effects are drowsiness, headaches and migraines, motor coordination impairment and/or upset stomach.A very serious allergic reaction rarely occurs. Many people using this medicine do not have serious side effects.Turn to your doctor or pharmacist for more details.In case you notice the effects not listed here, contact your doctor or pharmacist.

    Drug interactionsInform your doctor or chemist of all prescription and non-prescription medicines you are taking.Topiramate can interact with:* hormones for birth control, including implants or injections* carbamazepine* digoxin* medications for pain, sleep, or muscle relaxation* methazolamide* valproic acid.Turn to your doctor or pharmacist for more details.

    Missed doseIf you have missed your dose, take it as soon as you remember. If you see that it is near the time for the next dose, sk ip the missed dose and resume your usual dosing schedule. Do not take your dose twice.

    OverdoseIf you think you have used too much of this medicine seek emergency medical attention right away. The symptoms of overdose usually include chest pain, nausea, irregular heartbeat, and feeling light-headed or fainting.

    StorageStore your medicines at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Do not store your drugs in the bathroom. Keep all drugs away from reach of children and pets.

    DisclaimerWe provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.


    Source: Free Bonus! Free Bonus! Worldwide fastest delivery for Topamax pills of best quality! Topiramate extended release tablet strengths!

    Tuesday, 22 August 2017

    Readers Can Open Flipping Book on Tablets and Smartphones with PubHTML5

    Hong Kong, China -- (ReleaseWire) -- 08/22/2017 --Online digital publishing has become the new trend with the increase in the use of online platform for everything, including reading. PubHTML5 has become a leading digital publishing platform with its ability to create HTML5 based flipbooks, magazines and catalogs providing amazing results. The company understood the need to cater the rising number of mobile readers and thus they have optimized their functions to create flipping book for the mobile readers making them accessible from all devices including smartphones and tablets.

    Informing about the mobile-friendly flipping book, Anna Lee, Chief Designer of PubHTML5 said, "The number of mobile readers are increasing and will keep on increasing in the future too. Publishers require their work to be made easily accessible for their mobile readers as the number of such readers will keep on rising. Thus we have made sure that our clients get the highly mobile device optimized fli pping book for their readers."

    As told, the flipping book is created in a manner so that it can provide the smartphone and tablet readers a better experience, considering their small screen size. "The flipping books created through our platform are highly adaptable to any screen size. So no matter what device is being used to read the content, it adjusts itself as per the reader's device's screen size and give them a much better reading experience." she added. Not only this, the powerful, interactive and highly engaging HTML5 animations, which make the flipbook content really eye-catching, also are compatible to smartphones and tablets keeping the charm of animated content intact despite of the device it is being viewed at.

    PubHTML5 is a powerful platform for people to publish their flipping book online easily. With different options of publishing the work online and offline, the flipping book assists the publishers to reach out to a wide reader base in various different manners. Now with the optimization of the flipping book to make it highly adaptable to the mobile devices, the makers have made it really comfortable for the publishers to cater to the reading requirements of mobile readers and give them a great reading experience.

    About PubHTML5PubHTML5 offers cutting edge digital publishing software solutions to enhance the content delivery of businesses and individuals worldwide.

    For more information, please visit http://pubhtml5.com/.


    Source: Readers Can Open Flipping Book on Tablets and Smartphones with PubHTML5

    Monday, 21 August 2017

    Turn virtually any printer and tablet into a secure release station

    Presto Station Simple And Intuitive

    Presto Station gives users a simplified, beautiful, intuitive, and easy to use experience for secure release pull printing. Authenticate to Presto Station via your phone and Presto temporarily turns your phone into your personal release station.

    No Mobile, No Problem

    Login to Presto Station with a username or PIN code and release.

    Effortless Set Up

    Setting up Presto Station is fast.Install the app, login, select the printer, logout. That's it!Configuring a tablet for Presto Station can take as little as 30 seconds. Compare to traditional embedded solutions that can take 30 to 60 minutes per printer.

    Say Goodbye to Firmware Updates

    Updating Presto Station is as easy as updating an app.

    Incredible Savings

    No antiquated card readers. No firmware. No per printer secure release costs. Add to your savings by upcycling already owned but underutilized phones and tablets.

    Tablet Stands for Every Environment

    Your environment may demand aesthetically attractive kiosk stands. Or you may be concerned about theft. A wide spectrum of inexpensive off-the-shelf tablet stands are available to address your environment and design requirements.

    Features & Specs

    Enterprise Printing That Saves Time, Money, and Headache


    Source: Turn virtually any printer and tablet into a secure release station

    Sunday, 20 August 2017

    In Your State - Kamagra Tablets Uk Next Day Delivery

    Product DescriptionCommon useKamagra is a medication used to treat erectile dysfunction in men. This is analog version of Viagra, or sildenafil citrate, which is used for the treatment of sexual dysfunction in men. Kamagra increases the amount of blood passing to the penis.

    Dosage and direction100mg Kamagra dose acts in 45 minutes and lasts during 4-6 hours.

    PrecautionsBefore taking Kamagra notify your doctor if you suffer from allergies, anemia, eye diseases, cancer, high blood pressure or low blood pressure, irregular heart rhythm, heart failure, unstable chest pain, certain eye disorders, deformation of the penis or if you have a history of such conditions or take protease inhibitors for the treatment of HIV. Do not stand up fast from a lying or sitting position. Avoid drinking alcohol as it may worsen the side effects. Do not take Kamagra if you have already taken another ED medication. Before taking Kamagra warn your doctor if you use alprostadil (Caverject, Muse, Edex) or yohimbine (Yocon, Yodoxin, others).

    ContraindicationsKamagra is contraindicated in patients with allergy to the medication or those who are treated with nitrates (such as nitroglycerin). This combination can result in very low blood pressure that can lead to a stroke, a heart attack, or death. Do not take this medication if you are under 18 y.o.

    Possible side effectsSome patients may experience headache, diarrhea, dizziness, upset stomach, vomiting, nasal congestion. Such adverse effect like face blushing may be less expressed than in individuals taking Viagra. Kamagra can cause a rare but serious condition known as priapism or prolonged erection. Contact your health care provider at once if your erection continues longer than for hours.

    Drug interactionsKamagra should not be prescribed to patients treated with medications which contain organic nitrates. Kamagra blood levels are raised by erythromycin, ketoconazole, itraconazole and saquinavir. These medi cations are known to interact with Kamagra: bosentan (Tracleer); cimetidine (Tagamet, Tagamet HB); an antibiotic such as erythromycin (E-Mycin, Eryc, Ery-Tab) or clarithromycin (Biaxin); doxazosin (Cardura), prazosin (Minipress), Terazosin (Hytrin); HIV medicines such as indinavir (Crixivan), amprenavir (Agenerase), darunavir (Prezista), efavirenz (Sustiva), tipranavir (Aptivus), nevirapine (Viramune), saquinavir (Invirase, Fortovase), lopinavir/ ritonavir (Kaletra), fosamprenavir (Lexiva), ritonavir (Norvir), atazanavir (Reyataz), or nelfinavir (Viracept); an antifungal medication such as itraconazole (Sporanox) or ketoconazole (Nizoral); carbamazepine (Tegretol), phenobarbital (Luminal), or phenytoin (Dilantin); or rifampin (Rifadin, Rimactane) or rifabutin (Mycobutin).

    Missed doseKamagra is taken when needed so a missed dose is not supposed.

    OverdoseIf you overdosed Kamagra you may experience fainting, chest pain, nausea, irregular heartbeat, lightheadedness. Seek for immediate medical help.

    StorageStore in a tight container at room temperature away from moisture, sunlight, kids and pets.

    DisclaimerWe provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information on the site cannot be used for self-treatment and self-diagnosis. Апу specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.


    Source: In Your State - Kamagra Tablets Uk Next Day Delivery

    Saturday, 19 August 2017

    Suppliers Usa - Cialis Tablet 5mg

    Cialis 40 mg

    Package

    Per pill

    Price

    10 pills

    Free Viagra, Cialis or Levitra pills

    $3.75

    $37.46

    Add to cart

    20 pills

    Free Viagra, Cialis or Levitra pills

    $3.41

    $68.18

    Add to cart

    30 pills

    Free Viagra, Cialis or Levitra pills

    $3.30

    $98.89

    Add to cart

    60 pills

    Free Viagra, Cialis or Levitra pills

    $3.18

    $191.05

    Add to cart

    90 pills

    Free Viagra, Cialis or Levitra pills

    Free AirMail shipping

    $3.15

    $283.20

    Add to cart Cialis 20 mg

    Package

    Per pill

    Price

    10 pills

    Free Viagra, Cialis or Levitra pills

    $3.55

    $35.53

    Add to cart

    20 pills

    Free Viagra, Cialis or Levitra pills

    $2.46

    $49.13

    Add to cart

    30 pills

    Free Viagra, Cialis or Levitra pills

    $2.09

    $62.74

    Add to cart

    60 pills

    Free Viagra, Cialis or Levitra pills

    $1.73

    $103.54

    Add to cart

    90 pills

    Free Viagra, Cialis or Levitra pills

    $1.60

    $144.35

    Add to cart

    120 pills

    Free Viagra, Cialis or Levitra pills

    $1.54

    $185.16

    Add to cart

    180 pills

    Free Viagra, Cialis or Levitra pills

    Free AirMail shipping

    $1.48

    $266.78

    Add to cart

    270 pills

    Free Viagra, Cialis or Levitra pills

    Free courier delivery

    $1.44

    $389.21

    Add to cart

    360 pills

    Free Viagra, Cialis or Levitra pills

    Free courier delivery

    $1.42

    $511.63

    Add to cart Cialis 10 mg

    Package

    Per pill

    Price

    10 pills

    Free Viagra, Cialis or Levitra pills

    $3.55

    $35.53

    Add to cart

    20 pills

    Free Viagra, Cialis or Levitra pills

    $2.37

    $47.31

    Add to cart

    30 pills

    Free Viagra, Cialis or Levitra pills

    $1.97

    $59.08

    Add to cart

    60 pills

    Free Viagra, Cialis or Levitra pills

    $1.57

    $94.41

    Add to cart

    90 pills

    Free Viagra, Cialis or Levitra pills

    $1.44

    $129.74

    Add to cart

    120 pills

    Free Viagra, Cialis or Levitra pills

    $1.38

    $165.06

    Add to cart

    180 pills

    Free Viagra, Cialis or Levitra pills

    Free AirMail shipping

    $1.31

    $235.72

    Add to cart

    270 pills

    Free Viagra, Cialis or Levitra pills

    Free courier delivery

    $1.27

    $341.70

    Add to cart

    360 pills

    Free Viagra, Cialis or Levitra pills

    Free courier delivery

    $1.24

    $447.68

    Add to cart Cialis 5 mg

    Package

    Per pill

    Price

    10 pills

    Free Viagra, Cialis or Levitra pills

    $3.40

    $34.04

    Add to cart

    20 pills

    Free Viagra, Cialis or Levitra pills

    $2.27

    $45.32

    Add to cart

    30 pills

    Free Viagra, Cialis or Levitra pills

    $1.89

    $56.60

    Add to cart

    60 pills

    Free Viagra, Cialis or Levitra pills

    $1.51

    $90.45

    Add to cart

    90 pills

    Free Viagra, Cialis or Levitra pills

    $1.38

    $124.29

    Add to cart

    120 pills

    Free Viagra, Cialis or Levitra pills

    $1.32

    $158.14

    Add to cart

    180 pills

    Free Viagra, Cialis or Levitra pills

    Free AirMail shipping

    $1.25

    $225.83

    Add to cart

    270 pills

    Free Viagra, Cialis or Levitra pills

    Free courier delivery

    $1.21

    $327.37

    Add to cart

    360 pills

    Free Viagra, Cialis or Levitra pills

    Free courier delivery

    $1.19

    $428.90

    Add to cart Cialis 2.5 mg

    Package

    Per pill

    Price

    30 pills

    Free Viagra, Cialis or Levitra pills

    $1.40

    $42.03

    Add to cart

    60 pills

    Free Viagra, Cialis or Levitra pills

    $1.06

    $63.43

    Add to cart

    90 pills

    Free Viagra, Cialis or Levitra pills

    $0.94

    $84.82

    Add to cart

    120 pills

    Free Viagra, Cialis or Levitra pills

    $0.89

    $106.22

    Add to cart

    180 pills

    Free Viagra, Cialis or Levitra pills

    $0.83

    $149.02

    Add to cart

    270 pills

    Free Viagra, Cialis or Levitra pills

    Free AirMail shipping

    $0.79

    $213.21

    Add to cart

    360 pills

    Free Viagra, Cialis or Levitra pills

    Free AirMail shipping

    $0.77

    $277.40

    Add to cart

    INDICATIONS

    Cialis is indicated for the treatment of erectile dysfunction. Cialis is a phosphodiesterase type 5 (PDE5) inhibitor. It works by helping to increase blood flow into the penis during sexual stimulation. This helps you to achieve and maintain an erection.

    INSTRUCTIONS 

    Use Cialis as directed by your doctor.

  • Take Cialis by mouth with or without food.
  • For use as needed: Take Cialis at least 30 minutes before sexual activity, as directed by your doctor. Cialis may work for up to 36 hours after you take it.
  • For daily use: Take Cialis regularly at about the same time each day.
  • Check with your doctor before you eat grapefruit or drink grapefruit juice while you are taking Cialis.
  • For use as needed: If you miss a dose of Cialis and you still intend to engage in sexual activity, take it as soon as you remember. Continue to take it as directed by your doctor. For daily use: If you miss a dose of Cialis, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
  • DOSAGE

    For Use As Needed

  • The recommended starting dose of Cialis for use as needed in most patients is 10 mg, taken prior to anticipated sexual activity.
  • The dose may be increased to 20 mg or decreased to 5 mg, based on individual efficacy and tolerability. The maximum recommended dosing frequency is once per day in most patients.
  • Cialis for use as needed was shown to improve erectile function compared to placebo up to 36 hours following dosing. Therefore, when advising patients on optimal use of Cialis, this should be taken into consideration.
  •  For Once Daily Use

  • The recommended starting dose of Cialis for once daily use is 2.5 mg, taken at approximately the same time every day, without regard to timing of sexual activity.
  • The Cialis dose for once daily use may be increased to 5 mg, based on individual efficacy and tolerability.
  • Ask your health care provider any questions you may have about how to use Cialis.

    STORAGE

    Store Cialis at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Cialis out of the reach of children and away from pets.

    MORE INFO:

    Active Ingredient: Tadalafil.

    Inactive Ingredients: Croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.

    Do NOT use Cialis if:

  • you are allergic to any ingredient in Cialis
  • you have severe kidney problems and will be taking Cialis daily
  • you have severe liver problems or certain hereditary degenerative eye problems (eg, retinitis pigmentosa)
  • you have certain heart problems (eg, unstable angina, angina during sexual intercourse, uncontrolled irregular heartbeat), low blood pressure, or uncontrolled high blood pressure
  • you have had a heart attack within the past 90 days or you have had severe heart failure or a stroke within the past 6 months
  • you are taking a nitrate (eg, isosorbide, nitroglycerin) in any form (eg, tablet, capsule, patch, ointment), or nitroprusside
  • you have been advised by your doctor to avoid sexual activity because of heart problems
  • you use certain recreational drugs called "poppers" (eg, amyl nitrate or nitrite, butyl nitrate or nitrite)
  • you take another PDE5 inhibitor (eg, sildenafil, vardenafil) or another medicine that contains tadalafil.
  • Contact your doctor or health care provider right away if any of these apply to you.

    Some medical conditions may interact with Cialis. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
  • if you have allergies to medicines, foods, or other substances
  • if you have a deformed penis (eg, Peyronie disease, cavernosal fibrosis), blood cell problems (eg, sickle cell anemia, leukemia, multiple myeloma), or any other condition that may increase the risk of a prolonged erection (priapism)
  • if you have a history of a prolonged (more than 4 hours) or painful erection (priapism)
  • if you have a history of certain eye problems (eg, retinitis pigmentosa, sudden vision loss, optic neuropathy, macular degeneration) or hearing problems (eg, ringing in the ears, decreased hearing, hearing loss)
  • if you have a history of liver or kidney problems, dialysis, lung problems (eg, pulmonary veno-occlusive disease), high or low blood pressure, ulcers, bleeding problems, heart problems (eg, heart failure, irregular heartbeat, aortic stenosis, angina), or blood vessel problems
  • if you have a history of heart attack, stroke, or life-threatening irregular heartbeat.
  • Some medicines may interact with Cialis. Tell your health care provider if you are taking any other medicines, especially any of the following:

  • Alpha-blockers (eg, doxazosin), medicines for high blood pressure, nitrates (eg, isosorbide, nitroglycerin), or nitroprusside because severe low blood pressure with dizziness, lightheadedness, and fainting may occur
  • Azole antifungals (eg, itraconazole), HIV protease inhibitors (eg, ritonavir), macrolide antibiotics (eg, erythromycin), or telithromycin because they may increase the risk of Cialis's side effects
  • Barbiturates (eg, phenobarbital), carbamazepine, phenytoin, or rifampin because they may decrease Cialis's effectiveness.
  • This may not be a complete list of all interactions that may occur. Ask your health care provider if Cialis may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

    Important safety information:

  • Cialis may cause dizziness, drowsiness, fainting, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Cialis with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.
  • Cialis may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.
  • Do not drink large amounts of alcohol (eg, 5 drinks or more) while you take Cialis. Doing so may increase your risk of dizziness, headache, fast heartbeat, and low blood pressure.
  • Patients with heart problems who take Cialis may be at increased risk for heart-related side effects, including heart attack or stroke. Symptoms of a heart attack may include chest, shoulder, neck, or jaw pain; numbness of an arm or leg; severe dizziness, headache, nausea, stomach pain, or vomiting; fainting; or vision changes. Symptoms of a stroke may include confusion; vision or speech changes; one-sided weakness; or fainting. Contact your doctor or seek medical attention right away if you experience these symptoms.
  • Cialis may rarely cause a prolonged (eg, more than 4 hours) or painful erection. This could happen even when you are not having sex. If this is not treated right away, it could lead to permanent sexual problems such as impotence. Contact your doctor right away if this happens.
  • Cialis does not stop the spread of HIV or other sexually transmitted diseases (STDs) to others through sexual contact. Use barrier methods of birth control (eg, condoms) if you have HIV infection or an STD.
  • Cialis will not prevent pregnancy. If your partner may become pregnant and you wish to avoid pregnancy, be sure to use an effective form of birth control.
  • Cialis may uncommonly cause mild, temporary vision changes (eg, blurred vision, sensitivity to light, blue/green color tint to vision). Contact your doctor if vision changes persist or are severe.
  • Rarely, an eye problem called nonarteritic anterior ischemic optic neuropathy (NAION) has been reported in patients who took Cialis. This may lead to decreased vision or permanent loss of vision in some cases. If you notice a sudden decrease in vision or loss of vision in one or both eyes, contact your doctor right away.
  • Sudden decreases in hearing and loss of hearing have been reported in some patients who have taken Cialis. Sometimes they also noticed ringing in the ears or dizziness. If you notice a sudden decrease or loss of hearing, contact your doctor right away.
  • Do not use other medicines or treatments for ED while you are taking Cialis without first checking with your doctor.
  • Use Cialis with caution in the elderly; they may be more sensitive to its effects.
  • Cialis is not recommended for use in children younger 18 years. 
  • All medicines may cause side effects, but many people have no, or minor, side effects.

    Check with your doctor if any of these most common side effects persist or become bothersome:

    Dizziness; flushing; headache; heartburn; mild back or muscle pain; stomach upset; stuffy or runny nose.

    Seek medical attention right away if any of these severe side effects occur:

    Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; fainting; fast or irregular heartbeat; memory loss; numbness of an arm or leg; one-sided weakness; prolonged, painful erection; red, swollen, blistered, or peeling skin; ringing in the ears; seizures; severe or persistent back or muscle pain; severe or persistent dizziness; severe or persistent vision changes; sudden decrease or loss of hearing; sudden decrease or loss of vision in one or both eyes.

    This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

    Your order will be packed safely and secure and dispatched within 24 hours.This is how your parcel will look like, the images are photographs of real shipments.It has the size of a normal protected envelope and it does not disclose its contents.
    Source: Suppliers Usa - Cialis Tablet 5mg

    Thursday, 17 August 2017

    Gkids Acquires Japanese Sci-Fi Fantasy ‘Napping Princess’ For Fall Release

    Gkids, the distributor with nine Animated Feature Oscar nominations to its credit since 2010, has acquired North American rights to Napping Princess, the Kenji Kamiyama-helmed film that played the Annecy International Animation Film Festival this year and won the animated feature award at the Fantasia Film Festival. Gkids plans a September 8 platform bow in New York at Los Angeles, followed by a national rollout.

    The pic, previously known as Ancien and the Magic Tablet, is set in the near future and follows the journey of a young girl, Kokone, and her friend Morio as they set out to find Kokone's missing father who has been accused of a crime. Kokone soon realizes she must tap into a world only accessible through her dreams in order to solve the mystery. The film will bow theatrically in both its original Japanese language and a new English dubbed version. (Check out the dubbed trailer below.)

    Kamiyama's directing credits include East of Eden and Ghost in the Shell: Stand Alone Complex.

    "We fell in love with Kenji Kamiyama's unique vision in Napping Princess," said Gkids president David Jesteadt. "His blend of near-future science-fiction, family drama and detective story results in a high-octane, thought-provoking adventure that all ages can enjoy."

    Here's the trailer:


    Source: Gkids Acquires Japanese Sci-Fi Fantasy 'Napping Princess' For Fall Release

    Wednesday, 16 August 2017

    70,000 Incarcerated Individuals Working Toward College Degrees with Tablet Software

    DALLAS--(Business Wire)--Securus Technologies, a leading provider of civil and criminal justice technology solutions for public safety, investigation, corrections and monitoring announces industry-leading results in correctional education from its subsidiary - JPay.

    In early 2016, JPay launched JPay's Lantern, a first-of-its-kind initiative that enables mass education of incarcerated individuals through the use of tablets. Working with prison facilities in Georgia, Ohio, Louisiana and West Virginia, Lantern provides incarcerated individuals with the opportunity for educational attainment, creating a better chance of success upon release, thereby reducing recidivism.

    Since the launch of the groundbreaking program – the only education solution in corrections that offers college credits through the use of tablets – matriculation and overall participation have been unprecedented:

    • More than 70,400 incarcerated individuals have enrolled

    • Over 32,000 college credits have been earned in partnership with Ashland University

    • More than 4 million education course files have been downloaded onto JPay tablets

    • Lantern has contributed to a 456% increase in graduation rates for the Georgia Department of Corrections

    Thousands of students enrolled in Lantern after applying for the Second Chance Pell Grant pilot program, which was reinstated in June 2016. The grant allowed 12,000 incarcerated students across the country to enroll in postsecondary educational and training programs across 67 universities, and the first three students to earn their associate's degree recently graduated from Ashland University in Ohio using the Lantern platform.

    "JPay's Lantern created digital education opportunities that never existed. Leveraging a virtual classroom platform, thousands of incarcerated students have taken basic courses, earned college credits and received college degrees," said Jerry McGlone, Interim Director of the Gill Center at Ashland University. "These students have real hope and can even continue their education with Ashland University once released, an invaluable advantage in the reentry process. We couldn't have reached these milestones without a transformative program such as Lantern."

    The Georgia Department of Corrections (GDC) is the first to implement a state-wide digital educational initiative that utilizes Lantern, providing JPay tablets to more than 50,000 incarcerated individuals. By leveraging Lantern's digital education platform, the student population in 44 facilities has accessed more than 100 GED prep courses and downloaded remediation and enrichment content in general education modules. In addition to structured courses, GDC students have downloaded over 2.2 million KA Lite videos – a free offering through Lantern.

    "We believe education is the key to rehabilitation and post-release success. So when we realized we could leverage our extensive network to dramatically expand access to education, it was a no-brainer – we had to pursue it," said Errol Feldman, CEO of JPay. "And while the program's success to date has been gratifying, our goal is to extend the digital education revolution to the entire incarcerated population."

    Studies prove that education reduces recidivism. Digital solutions, such as JPay's Lantern, will put tablets in the hands of the incarcerated population so they can use their time served to earn a degree and be productive members of society upon release.

    ABOUT JPAY

    JPay, a Securus Technologies Company, designs, builds and deploys its technology to prisons and jails across the country, establishing correspondence to help educate and rehabilitate offenders. Serving more than 1.9 million offenders and parolees in 34 states, JPay makes the corrections process more convenient for offenders and their loved ones, while modernizing processes and increasing intelligence capabilities for corrections facilities. Products include money transfer services, tablets, email and video communications, education, games, music and more.

    ABOUT SECURUS TECHNOLOGIES

    Headquartered in Dallas, Texas, and serving more than 3,450 public safety, law enforcement and corrections agencies and over 1,200,000 inmates across North America, Securus Technologies is committed to serve and connect by providing emergency response, incident management, public information, investigation, biometric analysis, communication, information management, inmate self-service, and monitoring products and services in order to make our world a safer place to live. Securus Technologies focuses on connecting what matters®. To learn more about our full suite of civil and criminal justice technology solutions, please visit SecurusTechnologies.com.

    Securus Technologies, Inc.Russell Roberts, 972-277-0656rroberts@securustechnologies.com


    Source: 70,000 Incarcerated Individuals Working Toward College Degrees with Tablet Software

    Tuesday, 15 August 2017

    WarehouseOS Tablet Technology Preferred in Material Handling

    This press release was orginally distributed by SBWire

    Salt Lake City, UT -- (SBWIRE) -- 08/15/2017 -- Companies, such as Warehouse Mobile Solutions, makers of WarehouseOS, are making a strong movement to tablets as the preferred mechanism in materials handling. Warehouse Mobile Solutions tablet technology for warehouse management was recently featured in an article titled, "Warehouses Move to Tablet Technology," in AutomationMedia.com magazine.

    According to manufacturing journalist TR Cutler, "When it comes to productivity in the warehouse, too often plant managers and distribution center managers confuse how software and scanners impact the time it takes to fulfill customer orders. Having employees tethered to cumbersome hand-held terminals while trying to key in information on a small, hard-to-read screen prevents maximized picking rates and optimal order accuracy."

    New solutions are moving away from the RF guns and are demonstrating double picking rates after only 10 minutes of training with enclosures mounted to mobile picking carts. The company recently completed the installation of its Tablet Directed, Barcode/Order Fulfillment Solution, at Hot Shots Distributing located in Charlotte, North Carolina. For nearly two decades the company has been supplying the fiery food industry with over 1,400 fiery products. Utilizing the latest version of WarehouseOS, Version 2.0, fully integrated with Hot Shots ERP system, order fulfillment, and inventory management are now a paperless process.

    AutomationMedia.com is the industry's leading and popular technology website and useful resources for industrial technology enthusiasts. Industry professionals are using the Internet more than any other source to find information such as news, products, articles, application tools, technical resources, and job opportunities.

    To read the entire article, go to: http://bit.ly/207RSuB

    About WarehouseOSThe RF gun, constant verifications, small keypads, and hard to read screens are quickly becoming yesterday's technology. Tablets are replacing the RF gun. WarehouseOS, a new tablet-based Warehouse Operations System brings warehouses into the future today. Warehouse management systems have been around for a long time with too many companies still using the RF gun to conduct inventory management, scan in new items, and pick orders. The RF gun solutions typically cost double what modern solutions offer. WarehouseOS and associated apps have been developed to make everything about the warehouse easier and better. Apps allow small or large companies to receive products, manage inventory, perform cycle counting, conduct single picks or do batch picking, verify items picked and pack them into boxes.

    An easy to navigate user interface means warehouse personnel need almost no training before performing warehouse tasks. Receiving, put-away, picking, and packaging quickly become the easiest jobs on the floor. A team of experts in material handling equipment and solutions developed WarehouseOS to maximize the throughput of warehousing and distributing facilities. From small eCommerce, to high volume SKU facilities, from omni-channel companies to FMCG (fast moving consumer goods), WarehouseOS is equipped to handle everything. From small startups with simple needs to complex, large distribution centers, WarehouseOS is the table solution which enables manufacturers and distribution centers to be a step ahead of the competition.

    Learn more at http://www.warehousemobilesolutions.com and follow on Twitter @WarehouseOS.

    For more information on this press release visit: http://www.sbwire.com/press-releases/warehouseos-tablet-technology-preferred-in-material-handling-848042.htm


    Source: WarehouseOS Tablet Technology Preferred in Material Handling

    Monday, 14 August 2017

    Rugged Tablet PCs Market 2017 Emerging Trends

    (EMAILWIRE.COM, August 14, 2017 ) This report studies Rugged Tablet PCs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Panasonic, Getac, DT Research, Xplore and DRS Technology.

    For more information about this report at http://www.reportsweb.com/global-rugged-tablet-pcs-market-research-report-2017

    Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Rugged Tablet PCs in these regions, from 2011 to 2021 (forecast), like North America, Europe, China, Japan, Korea and Taiwan. Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Fully Rugged Tablets and Semi Rugged Tablets. Split by application, this report focuses on consumption, market share and growth rate of Rugged Tablet PCs in each application, can be divided into Manufacturing, Construction, Transportation & Distribution, Public safety, Retail, Medical and Government.

    Request a sample copy at http://www.reportsweb.com/inquiry&RW0001623196/sample

    Table of Content                             

    1 Rugged Tablet PCs Market Overview

    2 Global Rugged Tablet PCs Market Competition by Manufacturers

    3 Global Rugged Tablet PCs Production, Revenue (Value) by Region (2012-2017)

    4 Global Rugged Tablet PCs Supply (Production), Consumption, Export, Import by Regions (2012-2017)4.1 Global Rugged Tablet PCs Consumption by Regions (2012-2017)4.2 North America Rugged Tablet PCs Production, Consumption, Export, Import (2012-2017)4.3 Europe Rugged Tablet PCs Production, Consumption, Export, Import (2012-2017)4.4 China Rugged Tablet PCs Production, Consumption, Export, Import (2012-2017)4.5 Japan Rugged Tablet PC s Production, Consumption, Export, Import (2012-2017)4.6 Korea Rugged Tablet PCs Production, Consumption, Export, Import (2012-2017)4.7 Taiwan Rugged Tablet PCs Production, Consumption, Export, Import (2012-2017)

    5 Global Rugged Tablet PCs Production, Revenue (Value), Price Trend by Type5.1 Global Rugged Tablet PCs Production and Market Share by Type (2012-2017)5.2 Global Rugged Tablet PCs Revenue and Market Share by Type (2012-2017)5.3 Global Rugged Tablet PCs Price by Type (2012-2017)5.4 Global Rugged Tablet PCs Production Growth by Type (2012-2017)

    6 Global Rugged Tablet PCs Market Analysis by Application6.1 Global Rugged Tablet PCs Consumption and Market Share by Application (2012-2017)6.2 Global Rugged Tablet PCs Consumption Growth Rate by Application (2012-2017)6.3 Market Drivers and Opportunities6.3.1 Potential Applications6.3.2 Emerging Markets/Countries

    7 Global Rugged Tablet PCs Manufacturers Profiles/Analysis7.1 Panasonic7.1.1 Company Basic Information, Manufacturing Base and Its Competitors7.1.2 Rugged Tablet PCs Product Type, Application and Specification7.1.2.1 Product A7.1.2.2 Product B7.1.3 Panasonic Rugged Tablet PCs Production, Revenue, Price and Gross Margin (2015 and 2016)7.1.4 Main Business/Business Overview7.2 Getac7.2.1 Company Basic Information, Manufacturing Base and Its Competitors7.2.2 Rugged Tablet PCs Product Type, Application and Specification7.2.2.1 Product A7.2.2.2 Product B7.2.3 Getac Rugged Tablet PCs Production, Revenue, Price and Gross Margin (2015 and 2016)7.2.4 Main Business/Business Overview

    8 Rugged Tablet PCs Manufacturing Cost Analysis

    9 Industrial Chain, Sourcing Strategy and Downstream Buyers

    10 Marketing Strategy Analysis, Distributors/Traders

    11 Market Effect Factors Analysis

    12 Global Rugged Tablet PCs Market Forecast (2017-2022)

    13 Research Findings and Conclusion

    14 Appendix

    Purchase Complete Report at http://www.reportsweb.com/buy&RW000162319 6/buy/2900


    Source: Rugged Tablet PCs Market 2017 Emerging Trends

    Sunday, 13 August 2017

    Tablets and Capsules Packaging Market to Undertake Strapping Growth by 2024

    Deerfield Beach, FL -- (SBWIRE) -- 08/10/2017 -- Packaging is the technology used to safeguard product existing in any form, from getting damaged and contaminated specifically the consumables such as medicines and pharmaceuticals, and food and liquids. The packaging of medicines such as tablets and capsules demands high seal integrity, preventing accidental misuse, dosage direction, patient compliance, and delivery of products in complex transportation. The overall manufacturing process and machinery are majorly designed in a fully automatic way to avoid direct human contact which may lead to drug contamination. Pharmaceuticals packaging designs are based on the user's convenience, child resistance, and easy dispensing.

    Request Free Sample Report @ https://goo.gl/rps9Sp

    Tablets and capsules manufacturing and packaging market comprise various complex processes and composed materials. Thus based on the types of material used for tablets and capsules packaging, the global market is segmented as monolayer polyvinyl chloride PVC, polyvinylidene chloride (PVDC), chlorotriflouroethylene (CTFE), polystrene (PS), and aluminum blister foil. Further, based on the packaging products, the market is classified as blister, strip, and bottle. Various technological equipment used in packaging process is segmented as thermoforming and cold foaming, which are further sub-segments of the blister packaging methods as well as glass and plastic are the sub-segments of bottled type packaging. Based on end-user application, the market is segmented as pharmaceuticals and medical application. Geographically, the global fast moving consumer goods packaging market is segmented as North America, Europe, Middle East, Asia-Pacific, Latin America, and Rest of World.

    Request Report TOC (Table of Contents) @ https://www.zionmarketresearch.com/toc/tablets-and-capsules-packaging-market

    Constant technological advancements and modifications based on tablets and capsules di rectly impact the demand for tablets and capsules packaging. Rising number of the hospitalization and consumers' preference to preventive health check is also driving the market growth. Growing pharmaceuticals industries around the globe are also fostering the growth of tablets and capsule market. Further, government taking medical initiatives in many developing countries to maintain the health rate of the population is one of the vital factors responsible for boosting the demand for tablets and capsule packaging. The combination of creativity and packaging ideology to ease the delivery system and make the packaging more convenient for the consumers in terms of dosage are the developmental factors impacting the growth of the capsule and tablet packaging market positively. Strict regulations by regulatory bodies to reduce the adverse effects on human body owing to packaging materials may restrain the growth of the tablets and capsules packaging market to some extent.

    Browse det ail report @ https://www.zionmarketresearch.com/report/tablets-and-capsules-packaging-market

    Geographically, Asia Pacific is accounted as the leading market player for tablets and capsule packaging owing to significant growth in population and consecutive demand for medicines followed by North America and Europe.

    Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/tablets-and-capsules-packaging-market

    Some of the major players dominating the global tablets and capsule packaging market include Marchesini Group S.P.A, Bausch Strobel, Maschinenfabrik Ilshofen GmbH+Co., Robert Bosch GmbH, I.M.A. Industrial Machine Automatic S.P.A., Korber AG, 7 MG2 SRL, Multivac Group, Romaco Pharmatechnik GmbH, Uhlmann Group, and Optima Packaging Group GmbH.

    About Zion Market ResearchZion Market Research is an obligated company. We create futuristically, cutting edge, informative reports ranging from industry reports, a company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with Vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from Cardinal Industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    Contact Us:Zion Market Research4283, Express Lane,Suite 634-143,Sarasota, Florida 34249, United StatesTel: +49-322 210 92714USA/Canada Toll-Free No.1-855-465-4651Email: sales@zionmarketresearch.comWebsite: http://www.zionmarketresearch.comVi sit Our Blog: https://zionmarketresearch.wordpress.com/


    Source: Tablets and Capsules Packaging Market to Undertake Strapping Growth by 2024

    Saturday, 12 August 2017

    MoKo Case for All-New Amazon Fire 7 Tablet 2017 Release

    MoKo Case for All-New Amazon Fire 7 Tablet 2017 Release

    Copyright © 2001-2017 DealSnap.com Share a DealAll trademarks, service marks, product names, company names and logos appearing on DealSnap.com are the property of their respective owners.We are a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.Prices and offers are subject to change, DealSnap makes no representations or warranties as to the accuracy of the Content.


    Source: MoKo Case for All-New Amazon Fire 7 Tablet 2017 Release

    Thursday, 10 August 2017

    Tablets and Capsules Packaging Market to Undertake Strapping Growth by 2024

    Deerfield Beach, FL -- (SBWIRE) -- 08/10/2017 -- Packaging is the technology used to safeguard product existing in any form, from getting damaged and contaminated specifically the consumables such as medicines and pharmaceuticals, and food and liquids. The packaging of medicines such as tablets and capsules demands high seal integrity, preventing accidental misuse, dosage direction, patient compliance, and delivery of products in complex transportation. The overall manufacturing process and machinery are majorly designed in a fully automatic way to avoid direct human contact which may lead to drug contamination. Pharmaceuticals packaging designs are based on the user's convenience, child resistance, and easy dispensing.

    Request Free Sample Report @ https://goo.gl/rps9Sp

    Tablets and capsules manufacturing and packaging market comprise various complex processes and composed materials. Thus based on the types of material used for tablets and capsules packaging, the global market is segmented as monolayer polyvinyl chloride PVC, polyvinylidene chloride (PVDC), chlorotriflouroethylene (CTFE), polystrene (PS), and aluminum blister foil. Further, based on the packaging products, the market is classified as blister, strip, and bottle. Various technological equipment used in packaging process is segmented as thermoforming and cold foaming, which are further sub-segments of the blister packaging methods as well as glass and plastic are the sub-segments of bottled type packaging. Based on end-user application, the market is segmented as pharmaceuticals and medical application. Geographically, the global fast moving consumer goods packaging market is segmented as North America, Europe, Middle East, Asia-Pacific, Latin America, and Rest of World.

    Request Report TOC (Table of Contents) @ https://www.zionmarketresearch.com/toc/tablets-and-capsules-packaging-market

    Constant technological advancements and modifications based on tablets and capsules di rectly impact the demand for tablets and capsules packaging. Rising number of the hospitalization and consumers' preference to preventive health check is also driving the market growth. Growing pharmaceuticals industries around the globe are also fostering the growth of tablets and capsule market. Further, government taking medical initiatives in many developing countries to maintain the health rate of the population is one of the vital factors responsible for boosting the demand for tablets and capsule packaging. The combination of creativity and packaging ideology to ease the delivery system and make the packaging more convenient for the consumers in terms of dosage are the developmental factors impacting the growth of the capsule and tablet packaging market positively. Strict regulations by regulatory bodies to reduce the adverse effects on human body owing to packaging materials may restrain the growth of the tablets and capsules packaging market to some extent.

    Browse det ail report @ https://www.zionmarketresearch.com/report/tablets-and-capsules-packaging-market

    Geographically, Asia Pacific is accounted as the leading market player for tablets and capsule packaging owing to significant growth in population and consecutive demand for medicines followed by North America and Europe.

    Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/tablets-and-capsules-packaging-market

    Some of the major players dominating the global tablets and capsule packaging market include Marchesini Group S.P.A, Bausch Strobel, Maschinenfabrik Ilshofen GmbH+Co., Robert Bosch GmbH, I.M.A. Industrial Machine Automatic S.P.A., Korber AG, 7 MG2 SRL, Multivac Group, Romaco Pharmatechnik GmbH, Uhlmann Group, and Optima Packaging Group GmbH.

    About Zion Market ResearchZion Market Research is an obligated company. We create futuristically, cutting edge, informative reports ranging from industry reports, a company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with Vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from Cardinal Industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    Contact Us:Zion Market Research4283, Express Lane,Suite 634-143,Sarasota, Florida 34249, United StatesTel: +49-322 210 92714USA/Canada Toll-Free No.1-855-465-4651Email: sales@zionmarketresearch.comWebsite: http://www.zionmarketresearch.comVi sit Our Blog: https://zionmarketresearch.wordpress.com/


    Source: Tablets and Capsules Packaging Market to Undertake Strapping Growth by 2024